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Ocular complications associated with cutaneous lupus erythematosus (CLE) are less studied compared with those ones associated
with systemic lupus erythematosus (SLE).Themain ocular sites involved in patients affected by discoid lupus erythematosus (DLE)
are eyelids followed by orbit and periorbit, the least being cornea.Themost common complications are blepharitis usually affecting
the lower lid and associated with some type of lid lesion such as plaque or erythematosus patches and madarosis. Few cases with
LE profundus (LEP) and ocular complications are reported, but they are associated with orbital inflammatory syndrome and
severe complications. The main treatment prescribed is hydroxychloroquine with a dose of 200mg twice a day for 6 to 8 weeks.
Corticosteroids are also used. Intervals between the correct diagnosis and the beginning of the ocular symptoms are commonly
delayed. Ophthalmologist should be aware of the ocular manifestation of this autoimmune disease.
1. Introduction
Cutaneous lupus erythematosus (CLE) encompasses a wide
range of dermatologic manifestations and is two to three
times more frequent than systemic lupus erythematosus
(SLE) [1, 2].
Cutaneous lupus is divided into several subtypes, includ-
ing acute CLE (ACLE), subacute CLE (SCLE), and chronic
CLE (CCLE). CCLE includes discoid lupus erythematosus
(DLE), LE profundus (LEP), chilblain LE (CHLE), and LE
tumidus (LET) [3–5].
Discoid lesions are the most common form of CCLE [1–
6]. DLE is more frequent in women during their fourth and
fifth decade of life [7]. 60–80% of discoid lesions are localized
in sun exposed areas, such as head, neck, the scalp, ears, and
cheeks [8–12]. Occasionally, DLE can occur on mucosal sur-
faces, including lips and oral, nasal, and genital mucosa [1].
Cutaneous lesions begin as erythematosus maculae or
papules with a scaly surface, which gradually grow periph-
erally into larger adherent discoid plaques that heal leaving
an atrophic scar and pigmentary changes [1–6].
Histological examination of a longstanding active DLE
lesion reveals hyperkeratosis, dilated compact keratin-filled
follicles, vacuolar degeneration of the basal keratinocytes,
and an intensely inflammatory dermal infiltrate.
Serologically, DLE patients have a lower incidence of
ANA, dsDNA, Sm, U1RNP, and Ro/SSA antibodies, com-
pared to other CLE subtypes [13]. Ninety percent of DLE
lesions have a positive lupus band test with C3 and IgM as
the most common immune deposits [14].
Less common form of CLE is LEP. This is a painful
panniculitis with subcutaneous nodules in the lower dermis
and subcutaneous adipose tissue. The most common area
involvements are the upper arms and legs, face, and breasts.
Histology shows lobular panniculitis with a dense lympho-
cytic infiltrate [15]. LEP tends to a chronic course, leaving
atrophic scars [16].
Ocular complications in CLE are not so represented and
few cases are reported [17–56]. The aim of this paper is to
analyze the ocular association with this autoimmune disease
and offer a systematic view of the treatment regarding the
ocular involvement.
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2. Materials and Methods
Published journal articles are considered as the elements of
study and a specific literature search is performed in four
stages.
Stage 1 (unique citations). A Medline (National Library of
Medicine, Bethesda, Maryland, USA) search from January
1983 to December 2014 is performed to identify all arti-
cles describing ocular complications in patients with DLE.
Keyword searches used included “discoid lupus” + “ocular
complications” and “cutaneous lupus” and “ocular.”
Stage 2 (article retrieval). All abstracts from the Medline
searches are scrutinized to identify articles that reported
clinical results. Only journal articles published in English
are included. Copies of the articles are obtained, and their
bibliographies are searched manually for additional articles
published in peer-reviewed journals.
Stage 3 (article inclusion). Complete articles are reviewed
to identify those that reported original clinical data or
complication(s) of CLE. We decide to include 41 articles.
Stage 4 (article exclusion). We exclude all articles that
describe diagnosis different from CLE, published in a dif-
ferent language from English and where it is not possible to
obtain the full text form. We also avoid including articles
where the details regarding the disease or the treatment
prescribed for each patient reported are not available.
3. Results
A total of 41 articles are selected [17–56]. Tables 1 and 2
summarize data items from each paper. All papers are case
reports or case series. The total number of patients with CLE
and ocular complications is seventy-seven (111 eyes). Sixteen
subjects (20.8%) are male and sixty-one (79.2%) female. The
average age is 43.37 ± 15 years (range: 17–89 years). The
most represented ethnicity is Caucasian (25 cases; 32.5%)
followed by African (9 cases; 11.7%), Asian (6 cases; 7.8%),
Caribbean (4 cases; 5.2%), and Indian (1 case; 1.3%). In thirty-
two cases (41.6%), the ethnicity is not specified. Seventy-one
patients have a diagnosis of DLE (92.2%) and six patients
of LEP (7.8%). Interval between the correct diagnosis and
the beginning of the symptoms is an average of 41.40 ± 54.9
months in the group of patients with DLE, while in patients
with LEP it is shorter (an average of 1.8 ± 2.4 months). This
difference is statistically significant (𝑃 = 0.02).
Among patients with DLE, the ocular complications are
monolateral in 38 cases (53.5%) and bilateral in 33 cases
(46.5%).Themain ocular site involved in these patients is the
eyelids.This site is affected in 63 patients (88.7%) followed by
orbit and periorbit in six cases (8.4%) and cornea in 2 cases
(2.6%).
Extraocular involvement is commonly reported. Facial
lesions are described in 66 cases (93%). The most frequent
facial lesions are localized on forehead philtrum, malar
region, nose, and cheek and perioral nostril rim was less
common. Body lesions are found in four patients (5.6%).
The anatomic sites are arm back and knee. Alopecia is also
a finding represented in three cases (4.2%).
Blepharitis is the most represented ocular complication.
It affects thirty-eight patients (53.5%). The lower eyelid is
the most common site (27 cases; 38%), upper and lower lids
together (4 cases; 5.6%), and upper lid (1 case; 1.4%). In thirty-
nine cases (54.9%), this data is not reported. Telangiectasia
over the lid is described in two cases (2.8%).
Madarosis is associated with twenty cases (28.2%). In
sixteen cases (22.5%) lid lesions, such as lid plaques, are
described. In eight cases (11.3%) erythematosus papulae or
maculae close to the eyelid are described. Lid edema or
swelling is reported in nine cases (12.7%). Anomalies in lid
pigmentation are reported in three cases (4.2%). One case
of area of depigmentation and two cases of hyperpigmented
lesions are also reported.
Cornea involvement is described in two cases (5.6%)
such as stromal keratitis, but also in another two patients, a
punctate keratopathy is described associated with blepharitis.
ANA resulted to be negative in 21 cases (29.6%) and
positive in 15 cases (21.1%). The pattern most represented is a
speckled pattern (6 cases; 8.5%) followed by nucleolar pattern
(3 cases; 4.2%) and diffuse pattern (1 case; 1.4%). In five cases
(7%), the pattern is not specified.
The six patients (7.8%) with a diagnosis of LEP associated
with ocular complications show some peculiar features.
Monolateral form is the most representative (five cases;
85.7%). The ocular site more involved is orbit and periorbit
(five cases; 83.3%). In the other case, the ocular complication
involved eyelids. Facial skin lesions are described in almost
all cases (5 cases; 85.75%).
The treatment prescribed after the diagnosis of DLE is
hydroxychloroquine (40 cases; 51.9%).
The most common dosage prescribed is 200mg twice a
day. The weeks of treatment performed are reported in only
six cases. The average time of treatment is 28.8 ± 36.9 weeks
(range: 2–96).
Some cases of allergies to hydroxychloroquine are
reported.
The second choice of treatment is corticosteroid. This
is the first choice in all cases affected by LEP. Intravenous
methylprednisolone (1 g/day) or oral prednisolone with a
dosage between 20mg/day and 60mg/day is the most com-
mon choice. Some cases are treated by topical corticosteroids
drops, corticosteroid ointment, or tacrolimus ointment. In
two cases where the hydroxychloroquine is not prescribed,
the drug selected is mycophenolate. CO2 laser is used to
remove some lid lesions.
A good control of the disease is obtained in the majority
of the patients and the time of follow-up reported is 4 ± 11.7
months (range: 0–82). Important complications related to
orbital inflammatory syndrome such as central retinal artery
occlusion and enophthalmos are described in the group with
LEP.
4. Discussion
CLE is two to three times more frequent than SLE [2] but
ocular complications are less represented compared to SLE.
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Table 2: Clinical features of ocular LEP in each study.
Reference/country Studydesign
Age
(years)/gender
Ratio
Monolateral : Bilateral Ocular site
Ratio
ANA P :N Treatment
Sheehan-Dare and
Cunliffe (1988), UK
[22]
CR 47 m Monolateral Periorbital edema
Positive;
speckled
pattern
Prednisolone 40mg
Magee et al. (1991),
USA [25] CR 41 m Monolateral
Periorbital swelling and
proptosis —
Hydroxychloroquine
and prednisone∗
Inuzuka et al. (2001),
Japan [56] CR 71 f Bilateral
Eyelid plaque and
subcutaneous nodules Positive Prednisolone 30mg
Kao et al. (2010), USA
[55] CR 76 m Monolateral Enophthalmos
Positive;
diffuse
pattern
Prednisone 60mg
Sudhakar et al. (2012),
USA [54] CR 51 f Monolateral
Orbit and periorbit
inflammation associated
with CRAO
— —
Ohsie et al. (2012),
USA [53] CR 18 f Monolateral
Panniculitis involving orbit
and periorbit tissue Negative
Corticosteroid and
mycophenolate
mofetil∗
CR: case report; P: positive; N: negative; LEP: lupus erythematosus profundus; CRAO: central retinal artery occlusion.
∗Dosage not specified.
Ocular involvement in patients with CLE is not so
common. Among CLE subtypes, cases with DLE and ocular
complications are mostly described comparing cases affected
by LEP. In 1930, Aubaret [57] presented the first case of
chronic blepharitis in patients with DLE and, after 30 years,
Duke-Elder [58] and Donzi [59] reported additional cases.
Since the early 80s, seventy-one cases of ocular complications
associated with DLE are reported in the literature compared
to only six cases of patientswith LEP.Noocular complications
are reported for the other CLE subgroups: ACLE, SCLE,
CHLE, and LET.
In DLE, females are twice as likely to be affected as males.
Most patients are between 20 and 60 years old, with a mean
age of 42. Cutaneous manifestation of DLE may be slightly
more common in African Americans than in Caucasians
or Asians [14, 18, 60], but according to our data ocular
complications associated with DLE are more common in
Caucasian people. This data could be also biased because the
probability that the medical cases are reported and described
in the literature is higher in countries where the Caucasian
ethnicity is most represented.
The localized formofDLE is characterized by the involve-
ment of only the head and/or scalp and accounts for 70%
of DLE patients. The generalized form has more extensive
involvement and accounts for the remaining 30% of cases.
Facial involvement is present in 74% of DLE patients, with
the scalp and ear being the most commonly involved sites
[16]. According to our data, 93% of patients have some facial
lesions localized on forehead philtrum, malar region, nose,
and cheek.
The peculiar locations of the DLE lesions in the perioral,
periocular, and perinasal regions are described by Akagi et al.
[31] and they are associated with a relatively good prognosis.
This data is to be taken into account before prescribing
the treatment. Actually, these patients improved without any
treatment avoiding the risk of antimalarials drugs.
A biopsy of facial lesions and immunopathology is more
useful to make a definitive diagnosis. The typical findings
reported for DLE were the intense, thick granular IgG
and IgM and complement C3 deposition along the basal
membrane line [34].
Ocular manifestations of DLE reported in the litera-
ture include periorbital edema, blepharitis, madarosis, lid
scarring, entropion and ectropion, trichiasis, panniculitis,
conjunctivitis, hypertrophic/verrucous lesions, and stromal
keratitis [17–56].
Blepharitis is the most common sign and in the majority
of patients it is bilateral. In some cases the manifestation is
asymmetric and in few cases it is monolateral.
Most lesions seem to occur on the inferior portion
of the eyelid and are described as reddish, erythematosus,
slightly infiltrated plaques, with or without scales, atrophy, or
scarring.
Conjunctivitis, meibomitis, madarosis, and chronic eye-
lid erythema lid plaque lesions areas of anomaly pigmenta-
tion are reported. The differential diagnosis of DLE eyelid
involvement includes rosacea blepharoconjunctivitis, sebor-
rheic blepharitis, chronic staphylococcal blepharitis, contact
dermatitis, eczema, psoriasis, sebaceous cell carcinoma, lid-
involving sarcoidosis, lichen planus, lichenoid drug eruption,
and tinea faciei [18, 19, 24, 60, 61].
Recent studies have identified histopathologic features
of cutaneous lupus and this helped to distinguish it from
squamous cell malignancies in extrapalpebral locations
[62].
According to Papalas et al. [45], patients with CLE
affecting the eyelid are older than patients with squamous
cell carcinoma of the eyelid. In DLE the nodular/ulcerative
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eyelid lesions develop over a period of 6 months or less. A
full-thickness eyelid biopsy is required when the diagnosis
is doubtful, but it could lead to a poor cosmetic result and
recurrent wound dehiscence [24].
An important cornea involvement is described in two
cases [23]. The author reported an acute unilateral corneal
stromal infiltration and edema responded to corticosteroid
therapy without evidence of infection. He speculates that
the cause of corneal involvement in this group of patients
is related to a vasculitis near the limbus that may lead to
inflammation and corneal edema.
In addition, cases with punctate keratopathy are des-
cribed.
Orbital involvement is represented in the DLE patients,
although it is not the main site involved. On the contrary,
orbital involvement is the main site in patients with LEP.
Eyelid complications in patients with LEP have been reported
less frequently. Kearns et al. [63] reported a patient with LE
profundus principally in the region of left zygomatic arch but
extending to the lower eyelid and resulting inmild periorbital
oedema. Nowinski et al. [64] described three patients with
periorbital LEP, one of whom had proptosis and marked
periorbital oedema. In the other two cases the eyelid oedema
was less pronounced. Sheehan-Dare and Cunliffe [22] also
reported a patient with marked periorbital oedema. This
oedema was massive compared to common eyelid oedema
described in DLE patients. However, proptosis and conjunc-
tival involvement were not present while periorbital swelling
and important proptosis were reported by Magee et al.
[25].
Ohsie et al. [53] and Sudhakar et al. [54] described cases
affected by LEP and orbital inflammatory syndrome. One of
these cases [54] was complicated by a retinal artery occlusion
probably due to compression of optic nerve by intraorbital
fat. Kao et al. [55] reported a case of a man with diffuse red-
violet discoloration of the right upper and lower eyelids with
palpable induration and progressive enophthalmos.
The differential diagnosis of periorbital oedema is large.
Important causes of unilateral oedema include orbital
tumours that must be excluded. The presence of facial lesion
associated with CLE has to be evaluated in the differential
diagnosis. The percentage of males and females affected is
more similar compared to DLE.
Only 20% of DLE patients have a positive ANA [60] and
the most reported pattern among the patients with DLE and
ocular complications is the speckled one.
The goal of therapy is to prevent the progression of
existing lesions, improve patient appearance, and prevent
further lesions. Sunglasses and sunscreens are recommended
because ultraviolet exposure may exacerbate this disorder. In
all patients the standard treatment for blepharitis, such as lid
hygiene, doxycycline, and steroid creams, failed. The use of
topical and intralesional corticosteroids may sometimes be
helpful [21, 38, 45, 47], but the antimalarials are the mainstay
of therapy. Hydroxychloroquine (200–400mg orally per
day) may take up to 6 to 8 weeks for a response and require
monitoring every 6 months by ophthalmoscopy and visual
fields to screen for medication-related maculopathy
[14, 16, 65].
According to the data, the majority of patients responded
to systemic hydroxychloroquine therapy and when anti-
malarials cannot be used or if the lesion is resistant, immuno-
suppressive can be considered. Agents that have been re-
ported to be successfully used for DLE include azathio-
prine, dapsone, methotrexate, cyclophosphamide, thalido-
mide, retinoids, and interferon alpha-2 [14, 16, 27, 65].
Corticosteroids are mainly used in patients with LEP and
orbital inflammatory syndrome to control the severe inflam-
mation or associated with hydroxychloroquine therapy at the
beginning of the treatment.
5. Conclusion
There is delayed diagnosis in all cases of DLE, ranging from
1 month to 25 years especially when the manifestation of the
disease is a blepharitis. Distinguishing blepharitis associated
withDLE can be difficult and initialmisdiagnosis is common.
To increase the clinical ability among ophthalmologists to
perform a correct diagnosis, the following list reports the
main features of blepharitis associated with DLE which is
provided.
(1) Lower eyelids are the site most involved.
(2) The eyelids have lesions that appear as reddish patches
with slight infiltration and tender deformity of the
ciliary border.
(3) Other skin anomalies most commonly localized on
the face are present.
(4) Blepharitis is mainly bilateral, but often asymmetrical
and in few cases also monolateral.
(5) There is failure to standard blepharitis treatment.
(6) There is long history of blepharitis.
(7) Blepharitis associated to DLE is most common in
female gender and during the middle age.
Although ocular complications in CLE are quite rare, collab-
oration between rheumatologists, dermatologists, and oph-
thalmologists is fundamental to timely treat and prevent
further complications.Ophthalmologists should be trained to
detect these anomalies and refer to the specialist in doubtful
cases.
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